Interesting Endo: Fracture Risk & Endocrine Disruptors
Our April list includes predictors of fracture risk, endocrine-disrupting chemicals, and CV effects of thyroid dysfunction.
Interesting T2DM: Pharmacotherapy & Obesity Outcomes
Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.
Obesity Management: ENDO 2017 Highlights
Could corticosteroid use put your patients at a greater risk of metabolic syndrome?
Endo 2017: Men’s Health
Men’s health studies presented at ENDO 2017 included a possible prostate cancer treatment and the potential of hormone therapy to prevent frailty.
Endo 2017: Improve Diabetes, Obesity Care
Three studies from ENDO 2017 focused on improving patient care through brain stimulation, an artificial pancreas system, and videoconferencing.
ENDO 2017: Sleep Studies
Studies presented at ENDO 2017 examined the impact of sleep disorders on gestational diabetes, bone formation, and adolescents with and without diabetes.
ENDO 2017: Top Sessions
You won’t want to miss these top sessions and new features at this year’s Endocrinology Society’s annual meeting, April 1-4, in Orlando, FL.
Endo News Roundup: Diabetes and Cardiovascular Disease
Studies include drug-free remission of T2DM, and the impact of hyperglycemia and hypoglycemia on cardiovascular health.
Interesting Endo: T Trials & T1DM Self Care
Our March list includes Testosterone Trials results, self-management in patients transitioning to adult care, and cancer mortality risk with diabetes.
Interesting T2DM: Diabetic Retinopathy & Drug News
Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.
By clicking Accept, you agree to become a member of the UBM Medica Community.